Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab
Idiopathic granulomatous mastitis (IGM) is a rare, benign, inflammatory breast disease that primarily affects parous women within a period of five years post-partum. Cystic neutrophilic granulomatous mastitis (CNGM) is clinically identical to IGM, but histopathology demonstrates distinct central lip...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-01-01
|
| Series: | European Journal of Breast Health |
| Subjects: | |
| Online Access: |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/cystic-neutrophilic-granulomatous-mastitis-regress/49527
|
| _version_ | 1797924011050532864 |
|---|---|
| author | Le Wen Chiu Karen Goodwin Poonam Vohra Erin Amerson |
| author_facet | Le Wen Chiu Karen Goodwin Poonam Vohra Erin Amerson |
| author_sort | Le Wen Chiu |
| collection | DOAJ |
| description | Idiopathic granulomatous mastitis (IGM) is a rare, benign, inflammatory breast disease that primarily affects parous women within a period of five years post-partum. Cystic neutrophilic granulomatous mastitis (CNGM) is clinically identical to IGM, but histopathology demonstrates distinct central lipid vacuoles rimmed by neutrophils with an outer cuff of epithelioid histiocytes/granulomas, with inconsistent presence of Coryneform bacteria within the vacuoles. There is no consensus on the treatment for either IGM or CNGM, which may be managed surgically with wide local excision or mastectomy or medically with antibiotics, steroids, and steroid-sparing immunosuppressive agents. We present a 30-year-old woman with plaque psoriasis and CNGM whose breast symptoms resolved after treatment with the tumor necrosis factor alpha (TNF-α) inhibitor adalimumab, which has not previously been described as a treatment option for CNGM. |
| first_indexed | 2024-04-10T14:56:06Z |
| format | Article |
| id | doaj.art-f94918c37b144299ab5166a1550bb098 |
| institution | Directory Open Access Journal |
| issn | 2587-0831 |
| language | English |
| last_indexed | 2024-04-10T14:56:06Z |
| publishDate | 2022-01-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | European Journal of Breast Health |
| spelling | doaj.art-f94918c37b144299ab5166a1550bb0982023-02-15T16:07:23ZengGalenos Publishing HouseEuropean Journal of Breast Health2587-08312022-01-011819410110.4274/ejbh.galenos.2021.2021-7-213049054Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, AdalimumabLe Wen Chiu0Karen Goodwin1Poonam Vohra2Erin Amerson3 School of Medicine, University of California San Francisco, California, USA Department of Surgery, University of California San Francisco, California, USA Department of Pathology, University of California San Francisco, California, USA Department of Dermatology, University of California San Francisco, California, USA Idiopathic granulomatous mastitis (IGM) is a rare, benign, inflammatory breast disease that primarily affects parous women within a period of five years post-partum. Cystic neutrophilic granulomatous mastitis (CNGM) is clinically identical to IGM, but histopathology demonstrates distinct central lipid vacuoles rimmed by neutrophils with an outer cuff of epithelioid histiocytes/granulomas, with inconsistent presence of Coryneform bacteria within the vacuoles. There is no consensus on the treatment for either IGM or CNGM, which may be managed surgically with wide local excision or mastectomy or medically with antibiotics, steroids, and steroid-sparing immunosuppressive agents. We present a 30-year-old woman with plaque psoriasis and CNGM whose breast symptoms resolved after treatment with the tumor necrosis factor alpha (TNF-α) inhibitor adalimumab, which has not previously been described as a treatment option for CNGM. http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/cystic-neutrophilic-granulomatous-mastitis-regress/49527 cystic neutrophilic granulomatous mastitisidiopathic granulomatous mastitisadalimumabtumor necrosis factor alpha inhibitorcase report |
| spellingShingle | Le Wen Chiu Karen Goodwin Poonam Vohra Erin Amerson Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab European Journal of Breast Health cystic neutrophilic granulomatous mastitis idiopathic granulomatous mastitis adalimumab tumor necrosis factor alpha inhibitor case report |
| title | Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab |
| title_full | Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab |
| title_fullStr | Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab |
| title_full_unstemmed | Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab |
| title_short | Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab |
| title_sort | cystic neutrophilic granulomatous mastitis regression with the tumor necrosis factor α inhibitor adalimumab |
| topic | cystic neutrophilic granulomatous mastitis idiopathic granulomatous mastitis adalimumab tumor necrosis factor alpha inhibitor case report |
| url |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/cystic-neutrophilic-granulomatous-mastitis-regress/49527
|
| work_keys_str_mv | AT lewenchiu cysticneutrophilicgranulomatousmastitisregressionwiththetumornecrosisfactorainhibitoradalimumab AT karengoodwin cysticneutrophilicgranulomatousmastitisregressionwiththetumornecrosisfactorainhibitoradalimumab AT poonamvohra cysticneutrophilicgranulomatousmastitisregressionwiththetumornecrosisfactorainhibitoradalimumab AT erinamerson cysticneutrophilicgranulomatousmastitisregressionwiththetumornecrosisfactorainhibitoradalimumab |